Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.11
DVA's Cash to Debt is ranked higher than
57% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. DVA: 0.11 )
DVA' s 10-Year Cash to Debt Range
Min: 0.01   Max: 3.35
Current: 0.11

0.01
3.35
Equity to Asset 0.26
DVA's Equity to Asset is ranked higher than
55% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. DVA: 0.26 )
DVA' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.62
Current: 0.26

-0.35
0.62
Interest Coverage 3.61
DVA's Interest Coverage is ranked higher than
60% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 6.09 vs. DVA: 3.61 )
DVA' s 10-Year Interest Coverage Range
Min: 0.68   Max: 7.27
Current: 3.61

0.68
7.27
F-Score: 4
Z-Score: 1.85
M-Score: -2.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.18
DVA's Operating margin (%) is ranked higher than
82% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. DVA: 13.18 )
DVA' s 10-Year Operating margin (%) Range
Min: 5.25   Max: 20.7
Current: 13.18

5.25
20.7
Net-margin (%) 5.38
DVA's Net-margin (%) is ranked higher than
74% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 5.38 vs. DVA: 5.38 )
DVA' s 10-Year Net-margin (%) Range
Min: -10.19   Max: 10.21
Current: 5.38

-10.19
10.21
ROE (%) 14.29
DVA's ROE (%) is ranked higher than
85% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. DVA: 14.29 )
DVA' s 10-Year ROE (%) Range
Min: -45.11   Max: 223.91
Current: 14.29

-45.11
223.91
ROA (%) 3.70
DVA's ROA (%) is ranked higher than
72% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. DVA: 3.70 )
DVA' s 10-Year ROA (%) Range
Min: -7.16   Max: 9.04
Current: 3.7

-7.16
9.04
ROC (Joel Greenblatt) (%) 61.48
DVA's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. DVA: 61.48 )
DVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.56   Max: 83.1
Current: 61.48

26.56
83.1
Revenue Growth (%) 22.00
DVA's Revenue Growth (%) is ranked higher than
94% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. DVA: 22.00 )
DVA' s 10-Year Revenue Growth (%) Range
Min: -87.6   Max: 1149.5
Current: 22

-87.6
1149.5
EBITDA Growth (%) 20.00
DVA's EBITDA Growth (%) is ranked higher than
89% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. DVA: 20.00 )
DVA' s 10-Year EBITDA Growth (%) Range
Min: -88.4   Max: 1149.1
Current: 20

-88.4
1149.1
EPS Growth (%) 13.80
DVA's EPS Growth (%) is ranked higher than
82% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 9.30 vs. DVA: 13.80 )
DVA' s 10-Year EPS Growth (%) Range
Min: -28.6   Max: 128.9
Current: 13.8

-28.6
128.9
» DVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

DVA Guru Trades in Q1 2013

Jim Simons 87,250 sh (New)
John Keeley 1,842 sh (New)
Steven Cohen 16,336 sh (New)
Ray Dalio 13,459 sh (+41.73%)
Warren Buffett 14,973,906 sh (+10.04%)
Julian Robertson 136,900 sh (unchged)
Steve Mandel 1,989,505 sh (unchged)
Chuck Royce Sold Out
Alan Fournier 2,716,972 sh (-0.62%)
Pioneer Investments 989,615 sh (-26.8%)
Paul Tudor Jones 2,600 sh (-36.59%)
George Soros 38,000 sh (-60%)
Andreas Halvorsen 110,559 sh (-94.52%)
» More
Q2 2013

DVA Guru Trades in Q2 2013

Joel Greenblatt 5,322 sh (New)
Chuck Royce 1,600 sh (New)
Jim Simons 707,950 sh (+711.4%)
Steven Cohen 59,265 sh (+625.58%)
Warren Buffett 14,973,906 sh (unchged)
John Keeley 1,842 sh (unchged)
Steve Mandel Sold Out
George Soros Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Alan Fournier 2,675,972 sh (-1.51%)
Julian Robertson 120,900 sh (-11.69%)
Ray Dalio 11,400 sh (-15.3%)
Pioneer Investments 685,014 sh (-30.78%)
» More
Q3 2013

DVA Guru Trades in Q3 2013

John Burbank 4,410 sh (New)
Richard Perry 250,000 sh (New)
Ron Baron 600,000 sh (New)
Steve Mandel 6,302,027 sh (New)
Joel Greenblatt 81,807 sh (+668.57%)
Ray Dalio 89,400 sh (+292.11%)
Pioneer Investments 1,458,904 sh (+6.49%)
Warren Buffett 31,446,830 sh (+5.01%)
Jim Simons 1,460,200 sh (+3.13%)
John Keeley Sold Out
Julian Robertson Sold Out
Chuck Royce Sold Out
Alan Fournier 4,792,290 sh (-10.46%)
Steven Cohen 101,324 sh (-14.52%)
» More
Q4 2013

DVA Guru Trades in Q4 2013

Manning & Napier Advisors, Inc 1,518,586 sh (New)
Chuck Royce 2,100 sh (New)
Andreas Halvorsen 1,570,667 sh (New)
Paul Tudor Jones 7,052 sh (New)
Joel Greenblatt 221,775 sh (+171.1%)
Steve Mandel 8,470,777 sh (+34.41%)
Warren Buffett 36,461,294 sh (+15.95%)
Ray Dalio 93,437 sh (+4.52%)
Ron Baron Sold Out
Steven Cohen Sold Out
John Burbank Sold Out
Richard Perry Sold Out
Alan Fournier 3,637,892 sh (-24.09%)
Pioneer Investments 876,680 sh (-39.91%)
Jim Simons 296,600 sh (-79.69%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Steve Mandel 2013-12-31 Add 34.41%0.59%$55.03 - $63.39 $ 69.5119%8470777
Richard Perry 2013-12-31 Sold Out 0.36%$55.03 - $63.39 $ 69.5119%0
Warren Buffett 2013-12-31 Add 15.95%0.3%$55.03 - $63.39 $ 69.5119%36461294
Joel Greenblatt 2013-12-31 Add 171.1%0.21%$55.03 - $63.39 $ 69.5119%221775
Ron Baron 2013-12-31 Sold Out 0.16%$55.03 - $63.39 $ 69.5119%0
John Burbank 2013-12-31 Sold Out 0.01%$55.03 - $63.39 $ 69.5119%0
Julian Robertson 2013-09-30 Sold Out 1.9%$53.755 - $60.615 $ 69.5121%0
Steve Mandel 2013-09-30 New Buy1.6%$53.755 - $60.615 $ 69.5121%6302027
Richard Perry 2013-09-30 New Buy0.36%$53.755 - $60.615 $ 69.5121%250000
Ron Baron 2013-09-30 New Buy0.16%$53.755 - $60.615 $ 69.5121%600000
Joel Greenblatt 2013-09-30 Add 668.57%0.13%$53.755 - $60.615 $ 69.5121%81807
Ray Dalio 2013-09-30 Add 292.11%0.03%$53.755 - $60.615 $ 69.5121%89400
John Burbank 2013-09-30 New Buy0.01%$53.755 - $60.615 $ 69.5121%4410
John Keeley 2013-09-30 Sold Out $53.755 - $60.615 $ 69.5121%0
Steve Mandel 2013-06-30 Sold Out 1.2%$58.66 - $65.6 $ 69.5111%0
Julian Robertson 2013-06-30 Reduce -11.69%0.26%$58.66 - $65.6 $ 69.5111%120900
George Soros 2013-06-30 Sold Out 0.05%$58.66 - $65.6 $ 69.5111%0
Joel Greenblatt 2013-06-30 New Buy0.03%$58.66 - $65.6 $ 69.5111%5322
Warren Buffett 2013-03-31 Add 10.04%0.19%$54.15 - $61.68 $ 69.5120%14973906
George Soros 2013-03-31 Reduce -60%0.08%$54.15 - $61.68 $ 69.5120%38000
Ray Dalio 2013-03-31 Add 41.73%$54.15 - $61.68 $ 69.5120%13459
John Keeley 2013-03-31 New Buy$54.15 - $61.68 $ 69.5120%1842
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on DaVita HealthCare Partners Inc

Baron Funds Comments on DaVita HealthCare Partners Inc. - Nov 22, 2013


We initiated a position in DaVita HealthCare Partners, Inc. (DVA), a leading provider of kidney dialysis services for patients suffering from end stage renal disease. Through the acquisition of HealthCare Partners (HCP), DaVita also provides coordinated, outcomes-based medical care through physician networks in certain U.S. geographies. We think DaVita is well positioned to capitalize on trends in U.S. healthcare. The dialysis business generates steady growth driven by the increased prevalence of diabetes and has additional growth opportunities from international expansion and integrated care. HCP contracts with health plans and is accountable for the healthcare of its patients in exchange for a fixed fee. In this way, HCP is incentivized to deliver high quality healthcare at low cost. We think DaVita has an opportunity to bring HCP's successful model into new markets and is well positioned to benefit from the shift from fee-for-service reimbursement to risk-sharing and coordinated care. (Neal Kaufman)

From Ron Baron’s Baron Funds third quarter 2013 letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about DaVita HealthCare Partners Inc

Baron Funds Comments on DaVita HealthCare Partners Inc.
We initiated a position in DaVita HealthCare Partners, Inc. (DVA), a leading provider of kidney dialysis services for patients suffering from end stage renal disease. Through the acquisition of HealthCare Partners (HCP), DaVita also provides coordinated, outcomes-based medical care through physician networks in certain U.S. geographies. We think DaVita is well positioned to capitalize on trends in U.S. healthcare. The dialysis business generates steady growth driven by the increased prevalence of diabetes and has additional growth opportunities from international expansion and integrated care. HCP contracts with health plans and is accountable for the healthcare of its patients in exchange for a fixed fee. In this way, HCP is incentivized to deliver high quality healthcare at low cost. We think DaVita has an opportunity to bring HCP's successful model into new markets and is well positioned to benefit from the shift from fee-for-service reimbursement to risk-sharing and coordinated care. (Neal Kaufman)

From Ron Baron’s Baron Funds third quarter 2013 letter. Read more...
Buffett and Peers Hold Growing DaVita HealthCare, Four Sell Out
All year GuruFocus has been tracking numerous trades by Warren Buffett’s Berkshire Hathaway Inc. (BRK.A) (BRK.B) and his portfolio managers Ted Weschler and Todd Combs as they scoop up shares of DaVita HealthCare Partners Inc. (DVA), a growing kidney dialysis healthcare company. As DaVita continues to expand worldwide in Poland, Latin America, Taiwan and Malaysia, its second quarter 2013 income of $254.4 million has more than doubled since a year ago, and numerous billionaires are investing. Read more...
Alan Fournier's Top Five Positions
Alan Fournier is the founder and manager of Pennant Capital Management. Prior to creating Pennant, Fournier spent some time working at David Tepper’s Appaloosa Management managing global equity investments. During the second quarter Fournier sold out of four companies and made initial buys into eight new stocks. His second quarter portfolio held 46 stocks valued at $5.373 billion. The following five companies represent Fournier’s top five positions. Read more...
What Did Warren Buffett Buy? Quarterly Contest and Winners Announced
With Warren Buffett revealing his second quarter portfolio in the next few weeks, do you think you already know what he bought? GuruFocus is offering a classic book on value investing to anyone who correctly assesses the guru’s investing activity, as part of its “What Did Warren Buffett Buy?” quarterly contest. Read more...
Peter Lynch Chart Shows Berkshire Holding DaVita Overvalued
The new investment managers of Berkshire Hathaway (BRK.A)(BRK.B), Ted Weschler and Todd Combs, have generated great performance numbers since they join Berkshire. One of the reasons is that they bought into dialysis service provider DaVita. The stock of DaVita has had a tremendous run over the past four years. It gained 53% alone over the past 12 months. Read more...
Better Know a Company: Fresenius Medical Care (FMS)
History, Business: Fresenius Medical Care (FMS), or FMC for short, is an offshoot of Fresenius SE & Co., which traces its roots to a pharmacy founded in 1462. The Fresenius family assumed ownership in the 18th century and the newly acquired factory started producing dialysis machines in 1979. FMC was founded in 1996 after a merger of Fresenius Worldwide Dialysis and National Medical Care. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.60
DVA's P/E(ttm) is ranked higher than
61% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. DVA: 23.60 )
DVA' s 10-Year P/E(ttm) Range
Min: 11.29   Max: 30.68
Current: 23.6

11.29
30.68
P/B 3.20
DVA's P/B is ranked higher than
51% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. DVA: 3.20 )
DVA' s 10-Year P/B Range
Min: 2.37   Max: 11.65
Current: 3.2

2.37
11.65
P/S 1.30
DVA's P/S is ranked higher than
56% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. DVA: 1.30 )
DVA' s 10-Year P/S Range
Min: 0.77   Max: 2.33
Current: 1.3

0.77
2.33
PFCF 6.80
DVA's PFCF is ranked higher than
94% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. DVA: 6.80 )
DVA' s 10-Year PFCF Range
Min: 5.77   Max: 38.6
Current: 6.8

5.77
38.6
EV-to-EBIT 14.50
DVA's EV-to-EBIT is ranked higher than
68% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.82 vs. DVA: 14.50 )
DVA' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 21.3
Current: 14.5

8.3
21.3
PEG 1.50
DVA's PEG is ranked higher than
78% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. DVA: 1.50 )
DVA' s 10-Year PEG Range
Min: 0.23   Max: 3.42
Current: 1.5

0.23
3.42
Shiller P/E 28.60
DVA's Shiller P/E is ranked lower than
51% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. DVA: 28.60 )
DVA' s 10-Year Shiller P/E Range
Min: 14.7   Max: 73.06
Current: 28.6

14.7
73.06

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
DVA's Price/DCF (Projected) is ranked higher than
73% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. DVA: 0.90 )
DVA' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 2.58
Current: 0.9

0.84
2.58
Price/Median PS Value 1.00
DVA's Price/Median PS Value is ranked higher than
65% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. DVA: 1.00 )
DVA' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 3.73
Current: 1

0.33
3.73
Price/Peter Lynch Fair Value 1.80
DVA's Price/Peter Lynch Fair Value is ranked higher than
52% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. DVA: 1.80 )
DVA' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 2.71
Current: 1.8

0.48
2.71
Earnings Yield (Greenblatt) 6.90
DVA's Earnings Yield (Greenblatt) is ranked higher than
70% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 5.50 vs. DVA: 6.90 )
DVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 12.1
Current: 6.9

4.7
12.1
Forward Rate of Return (Yacktman) 17.55
DVA's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. DVA: 17.55 )
DVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 10.8   Max: 63.1
Current: 17.55

10.8
63.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, FSNUY, BDUUF, SKHCY » details
Traded in other countries:TRL.Germany
DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company operates or provides administrative services to over 1,809 outpatient dialysis centers located in 43 states and the District of Columbia, serving approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 700 hospitals and related laboratory services. The Company's dialysis and related lab services business accounts for approximately 93% of its consolidated revenues. Many of the Company's outpatient dialysis centers offer services for home dialysis patients, mainly CAPD and CCPD. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services, excluding physician services, to patients in approximately 900 hospitals. The Company renders these services for a contracted per-treatment fee that is individually negotiated with each hospital. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 33 outpatient dialysis centers, in which it either owns a non-controlling interest, or are wholly-owned by third parties, under management and administrative services agreements. The Company engages in organized and systematic efforts through its quality management programs to monitor and improve the quality of services it delivers. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide